Overview

An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of UCB0599 in Study Participants With Parkinson's Disease

Status:
Enrolling by invitation
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to estimate the pharmacodynamic effects of UCB0599 on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Biopharma SRL